Neuroprotection Exploratory Trials in PD (NET-PD)

帕金森病（PD）是一种缓慢但无情地进行性神经退行性疾病， 临床症状的时间依赖性恶化抗PD药物有效地改善了大多数主要的 帕金森病的症状和体征在大多数患者。然而，传统的药物治疗并不 随着时间的推移，改善运动功能和功能性残疾的进行性恶化。因此，在本发明中， 可以减缓临床进展、增强受损神经元的修复、恢复或 增强多巴胺（DA）系统残余部分的功能是非常必要的。因为疾病 进展通常是缓慢的，用靶向多种致病机制的化合物治疗可以是有效的。 NET-PD多中心试验旨在测试 潜在的神经保护化合物在早期PD患者中的功效。的化合物 将在大型双盲安慰剂对照中对无效研究中确定有效的药物进行检测 问题研究NINDS的神经变性和临床试验组正在申请新的 中心合作进行临床试验，以测试潜在的神经保护剂。我们提议成为 网络PD中心。肯塔基州大学的运动障碍中心为大列克星敦提供服务 地区，主要是城市社区和农村，中部，东部和东南部的63个县 肯塔基州。此外，我们治疗了几名居住在西弗吉尼亚州和南俄亥俄州的PD患者（-25）。 我们跟踪约600名PD患者，平均每月诊断5名新的PD患者。所以我们 预计每月能够入组1-2例早期PD患者进入初步试验。

Parkinson's disease (PD) is a slowly but relentlessly progressive neurodegenerative disorder resulting in a time-dependent worsening of clinical symptoms. Anti-PD drugs effectively ameliorate most of the major parkinsonian signs and symptoms in a majority of patients. However, traditional drug therapies do not modify the progressive deterioration of motor function and functional disability worsens over time. Thus, disease modifying drugs that can slow clinical progression, enhance repair of damaged neurons, restore or enhance function of residual parts of the dopamine (DA) system are much needed. Since disease progression is generally slow, treatment with compounds that target multiple pathogenic mechanisms can be implemented over a relatively long period of time.The NET-PD multicenter trial is aimed at testing the efficacy of potential neuroprotective compounds in early stage PD patients. Compounds that are ascertained to be effective in the Futility studies will be tested in large double-blinded placebo control studies. The Neurodegeneration and Clinical Trial Groups of the NINDS are requesting applications for new centers to collaborate in clinical trials to test potential neuroprotective agents. We are proposing to become a NET-PD center. The Movement Disorders Center at University of Kentucky serves the greater Lexington area, a primarily urban community and the largely rural, 63-county area of central, eastern, and southeastern Kentucky. In addition, we treat several PD patients (-25) who reside in West Virginia and Southern Ohio. We follow -600 PD patients and we diagnose on average 5 new PD patients per month. Therefore, we expect to be able to enroll 1-2 early stage PD patients per month into the Pilot Trials.